STERIS plc (STE)
Market Cap | 23.44B |
Revenue (ttm) | 5.46B |
Net Income (ttm) | 614.64M |
Shares Out | 98.37M |
EPS (ttm) | 6.21 |
PE Ratio | 38.35 |
Forward PE | 23.69 |
Dividend | $2.28 (0.96%) |
Ex-Dividend Date | Jun 10, 2025 |
Volume | 737,182 |
Open | 238.59 |
Previous Close | 238.53 |
Day's Range | 236.73 - 240.63 |
52-Week Range | 200.98 - 252.79 |
Beta | 0.94 |
Analysts | Buy |
Price Target | 261.00 (+9.53%) |
Earnings Date | Aug 5, 2025 |
About STE
STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights,... [Read more]
Financial Performance
In 2024, STERIS's revenue was $5.46 billion, an increase of 6.24% compared to the previous year's $5.14 billion. Earnings were $614.64 million, an increase of 62.50%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for STE stock is "Buy." The 12-month stock price forecast is $261.0, which is an increase of 9.53% from the latest price.
News

U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report 2025-2030 Featuring STERIS, The Brewer Company, Midmark Corp. (Ritter Midmark), Clinton Industries, UMF Medical and More
Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Uro...

Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.
Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tai...

STERIS plc (STE) Q4 2025 Earnings Call Transcript
STERIS plc (NYSE:STE) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer Da...

Why This Medical Equipment Stock Is Today's S&P 500 Winner
Steris beat quarter.y earnings and revenue expectations and got a price target boost from Morgan Stanley.

Steris forecasts annual profit above estimates on strong medical equipment sales
Medical equipment maker Steris forecast annual profit above analysts' estimate on Wednesday, banking on strength in its biggest segment that sells sterilization products, sending its shares up more th...

Steris Fiscal Fourth-Quarter 2025 Financial Results: Just the Numbers
Medical equipment maker Steris (STE) on Wednesday afternoon reported fiscal fourth-quarter 2025 financial results. A summary of its key numbers is below.

STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, ...

STERIS Declares Dividend of $0.57 per share
DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. T...

10 Undervalued Dividend Growth Stocks: May 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and anoth...

STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025
DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and...

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with manage...

STERIS plc (STE) Q3 2025 Earnings Call Transcript
STERIS plc (NYSE:STE) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Offic...

Steris lowers annual profit forecast due to a stronger dollar
Medical equipment maker Steris lowered its annual profit forecast on Wednesday, citing the impact of a stronger dollar.

STERIS Announces Financial Results for Fiscal 2025 Third Quarter
DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total...

STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025
DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter fina...

STERIS Announces Outcome of Ethylene Oxide Trial
DUBLIN, IRELAND, Jan. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix O...

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EP...

STERIS plc (STE) Q2 2025 Earnings Call Transcript
STERIS plc (STE) Q2 2025 Earnings Call Transcript

Steris beats quarterly estimates on continued demand for medical procedures
Medical equipment maker Steris beat second-quarter profit estimates on Wednesday, on continued demand for non-urgent medical procedures that boosted sales of its surgical and examination tools.

STERIS Announces Financial Results for Fiscal 2025 Second Quarter
DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) -- - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. ...

STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024
DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 second quarter fin...

STERIS plc (STE) Enters New $1.1 Billion Revolving Credit Agreement
STERIS plc (STE, Financial), along with its subsidiaries STERIS Corporation, STERIS Limited, and STERIS Irish FinCo Unlimited Company, has entered into a significant financial arrangement with various...

15 Upcoming Dividend Increases Including A King
This week, 15 companies, including Dividend King Stanley Black & Decker, are set to increase dividends, with SWK extending its 57-year streak by 1.2%. My strategy focuses on buying, holding, and addin...

STERIS to Present at the Morgan Stanley Healthcare Conference
DUBLIN, IRELAND, Aug. 26, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York C...

Steris: Q2 Numbers Solidify Buy Thesis
STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base....